Beam Therapeutics 

Beam Therapeutics 

Yahoo Finance • 8 days ago

Most shorted stocks on Wall Street

[short sale] abluecup As October begins, investors are keeping a close eye on heavily shorted stocks that could see heightened volatility. The latest mid- to mega-cap screen shows 39 stocks with short interest above 20% of shares outstan... Full story

Yahoo Finance • 15 days ago

Cathie Wood's Ark Invest weekly recap: boosts Meta, Rocket Lab; cuts Tempus AI, CrowdStrike

Cathie Wood’s Ark Invest boosted its technology, biotechnology, and space exposure last week, led by purchases of more than 51K shares of Meta Platforms (META [https://seekingalpha.com/symbol/META]) worth $38.2M and roughly 360K shares of... Full story

Yahoo Finance • 21 days ago

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

You may have a strong opinion about Cathie Wood, but the aggressive growth investor is used to aggressive opinions. She is relentless in pursuing market opportunities in emerging technologies as the founder and CEO of Ark Invest. She doesn... Full story

Yahoo Finance • 28 days ago

Cathie Wood Makes Striking Switch Between AI Stock Giants

This article first appeared on GuruFocus. Cathie Wood's Ark Invest made a sharp rotation across technology and biotechnology stocks last week, buying roughly $28 million of Meta Platforms (NASDAQ:META) while selling a nearly identical dol... Full story

Yahoo Finance • 29 days ago

Cathie Wood buys $27.9 million of surging megacap stock

Cathie Wood, head of Ark Investment Management, often buys her favorite tech stocks when she sees a new opportunity. That's what she did last week, pouring $27.9 million into Meta Platforms (META) as the company pushes deeper into AI. La... Full story

Yahoo Finance • 2 months ago

Biotech Breakout: What's in focus after Moderna's cancer win?

[mRNA or messenger RNA. The concept of mRNA vaccine. Innovative methods to treat virus. 3d render] Krot Studio INVESTORS SHOULD KNOW: A major Phase 3 trial win from Moderna (MRNA [https://seekingalpha.com/symbol/MRNA]) and Merck (MRK [htt... Full story

Yahoo Finance • 2 months ago

4 Gene-Editing Biotech Stocks Worth Watching for Long-Term Gains

Gene editing is emerging as a potentially transformative approach to medicine because it seeks to address disease at its genetic source rather than primarily managing downstream symptoms. Unlike conventional therapies that may require chro... Full story

Yahoo Finance • 2 months ago

Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD)

Updated BEAM-302 Phase 1/2 Clinical Data Selected for Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026 Dosing Complete for All Adult and Adolescent Patients in Phase 1/2 BEACON Trial of Risto-cel in... Full story

Yahoo Finance • 2 months ago

Most and least shorted mid- to mega-cap healthcare stocks at the end of July

[Health Care Medical Stock Market Industry Sector Wall Street Buildings 3d Illustration] iQoncept/iStock via Getty Images Short interest data from late July 2026 highlights deeply divided investor sentiment across the healthcare sector. S... Full story

Yahoo Finance • 3 months ago

Scribe’s Genetic Editing Aims to Prevent Heart Attacks

Scribe Therapeutics shares are up 30% since it raised $125 million in its initial public offering Friday. The cash will fund three clinical trials testing whether Scribe’s one-time treatments can halve the risk of heart attacks and strok... Full story

Yahoo Finance • 3 months ago

ARK Invest snaps up $16.7M in SPCX shares, trims Deere exposure

[Man looking at currency trading app on his smart phone from his home office] Alistair Berg * Cathie Wood’s ARK Invest doubled down on its aerospace bet on Wednesday, snapping up 122,807 shares of Space Exploration Technologies Corp (SP... Full story

Yahoo Finance • 3 months ago

Bank of America Securities Maintains Buy Rating for Beam Therapeutics (BEAM)

Beam Therapeutics Inc. (NASDAQ:BEAM) is one of the 10 affordable biotech stocks to buy right now. On July 8, Alec Stranahan from Bank of America Securities reaffirmed his Buy rating for Beam Therapeutics Inc. (NASDAQ:BEAM), following a fa... Full story

Yahoo Finance • 3 months ago

Prime Medicine (PRME) Reaches Positive Resolution to Arbitration with Beam Therapeutics

Prime Medicine, Inc. (NASDAQ:PRME) is one of the best strong buy penny stocks to invest in now. Prime Medicine, Inc. (NASDAQ:PRME) announced on July 8 a positive, binding resolution of its previously disclosed arbitration with Beam Therape... Full story

Yahoo Finance • 3 months ago

Cathie Wood buys $22.8 million of surging tech stock

Cathie Wood, CEO of Ark Investment Management, is known for investing in high-growth tech companies. She'll even add to positions amid strong gains, and that's what she just did, adding shares of a megacap stock that has surged 14.8% over... Full story

Yahoo Finance • 3 months ago

Prime Medicine gains after winning arbitration with Beam Therapeutics

[Genetic engineering] Andy/iStock via Getty Images Prime Medicine (PRME [https://seekingalpha.com/symbol/PRME]) added ~8% in the premarket on Wednesday after an arbitration tribunal sided with the gene editing company in connection with a... Full story

Yahoo Finance • 4 months ago

Cathie Wood buys $11.5 million of battered tech stock

Cathie Wood, chief of Ark Investment Management, likes to double down on her favorite tech stocks when the prices are falling, hoping for a bargain. That's what Wood just did, adding shares of Coinbase after weeks of tumbling. In 2025, W... Full story

Yahoo Finance • 4 months ago

Draft FDA guidance could be a boon for gene therapy developers

[Genetic Medicine And DNA Therapy] narvo vexar * The US FDA has issued draft guidance intended to accelerate the development of gene and cell therapies. * The agency hopes the document will enhance the R&D process for the treatments "... Full story

Yahoo Finance • 5 months ago

Better Gene-Editing Stock: CRISPR Therapeutics or Beam Therapeutics?

Key Points CRISPR Therapeutics has an approved product and several gene editing medicines in development. Beam Therapeutics is exploring ways to develop safer gene-editing therapies. One of these stocks is a lot less risky than the other.... Full story

Yahoo Finance • 5 months ago

Hedge Fund Drops $40 Million on Gene-Editing Biotech Beam. Is It a Buy?

Key Points Initiated 1,446,375-share position in Beam Therapeutics; estimated trade size $40.13 million (quarterly average price). Quarter-end stake valued at $34.47 million, a net position change reflecting both trading and price movemen... Full story

Yahoo Finance • 5 months ago

Beam Therapeutics to Present Updated Biomarker Data from Phase 1/2 BEACON Trial Further Underscoring Risto-cel’s Ability to Restore Red Blood Cell Health and Function in Sickle Cell Disease at EHA2026

Beam logo CAMBRIDGE, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will present updated... Full story